|
|
|
Insider
Information: |
Rothera Mark |
Relationship: |
President and CEO, Dir... |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
232,348 |
|
Indirect Shares
|
19,216 |
|
|
Direct
Value |
$1,337,045 |
|
|
Indirect Value
|
$349,379 |
|
|
Total
Shares |
251,564 |
|
|
Total
Value |
$1,686,424 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
0
|
Stock
price went up :
|
2
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
2.0
|
0.0
|
Percentage
Gain/Loss : |
41.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
Officer |
2012-04-30 |
4,813 |
|
0 |
Premium* |
|
PTC Therapeutics, Inc. |
PTCT |
Chief Commercial Officer |
2017-05-24 |
33,739 |
2017-05-24 |
9,216 |
Premium* |
|
Orchard Therapeutics Plc |
ORTX |
Officer, Director |
2020-01-01 |
93,796 |
2020-01-01 |
10,000 |
Premium* |
|
Viracta Therapeutics Ord Shs |
VIRX |
President and CEO, Dir... |
2023-12-01 |
100,000 |
2023-11-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2015-07-21 |
4 |
OE |
$10.85 |
$99,994 |
D/D |
9,216 |
9,216 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2015-10-20 |
5 |
GA |
$0.00 |
$0 |
I/I |
9,216 |
9,216 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2015-10-20 |
5 |
GD |
$0.00 |
$0 |
D/D |
9,216 |
0 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2016-01-15 |
4 |
OE |
$10.85 |
$33,906 |
D/D |
3,125 |
3,125 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2016-03-03 |
4 |
B |
$6.23 |
$12,460 |
D/D |
2,000 |
5,125 |
2.74 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2016-09-26 |
4 |
OE |
$10.85 |
$23,870 |
D/D |
2,200 |
7,325 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2016-10-10 |
4 |
OE |
$10.85 |
$21,158 |
D/D |
1,950 |
9,275 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2016-11-14 |
4 |
OE |
$10.85 |
$21,060 |
D/D |
1,941 |
11,216 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2017-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
22,523 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2017-01-17 |
4 |
OE |
$10.85 |
$33,906 |
D/D |
3,125 |
25,648 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2017-02-16 |
4 |
OE |
$10.85 |
$33,906 |
D/D |
3,125 |
28,773 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2017-03-15 |
4 |
OE |
$10.85 |
$32,181 |
D/D |
2,966 |
31,739 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Commercial Officer |
|
2017-05-24 |
4 |
OE |
$10.85 |
$21,700 |
D/D |
2,000 |
33,739 |
0 |
- |
|
ORTX |
Orchard Therapeutics Plc |
See RemarksOfficer |
|
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
93,796 |
|
- |
|
ORTX |
Orchard Therapeutics Plc |
See RemarksOfficer |
|
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,000 |
|
- |
|
VIRX |
Viracta Therapeutics Ord ... |
President and CEO |
|
2023-11-30 |
4 |
B |
$0.49 |
$25,734 |
D/D |
52,094 |
52,094 |
2.81 |
% |
|
VIRX |
Viracta Therapeutics Ord ... |
President and CEO |
|
2023-12-01 |
4 |
B |
$0.49 |
$23,627 |
D/D |
47,906 |
100,000 |
2.81 |
% |
|
42 Records found
|
|
Page 2 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|